Brain MR imaging abnormalities, their distribution, locations of reduced diffusion, size of the largest WM lesion, %ADCR values, and clinical outcomes
| No. | Age (yr) | Sex | Size (cm) | Underlying Dx | Etiologies | Groups | Regions of Red. Diffusion | FLAIR Severity | DWI Severity | %ADC Red. | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 16 | M | 4.2 × 2.2 | ALL | Methotrexate | C | Fr, CS/CR | 1 | 1 | 0.32 | 1 |
| 2 | 14 | M | 2.1 × 0.8 | ALL | Methotrexate | C | Fr, CS/CR | 1 | 1 | 0.16 | 0 |
| 3 | 18 | M | 4.5 × 2.6 | ALL | Methotrexate | C | Fr+P, CS/CR | 1 | 2 | 0.39 | 2 |
| 4 | 16 | F | 2.1 × 1.8 | ALL | Cytarabine | C | Fr, CS/CR | 1 | 1 | 0.35 | 2 |
| 5 | 11 | M | 4.5 × 2.2 | ALL | Methotrexate | C | Fr, CS/CR, CC | 0 | 2 | 0.36 | 2 |
| 6 | 11 | F | 4.1 × 1.8 | ALL | Methotrexate | C | Fr+P, CS/CR | 1 | 2 | 0.41 | 2 |
| 7 | 14 | F | D | AML | Fludarabine | C | D, CS/CR, CC, Th | 4 | 4 | 0.32 | 3 |
| 8 | 17 | F | 2.3 × 0.4 | ALL | Methotrexate | C | Fr+P, CS/CR | 2 | 2 | 0.32 | 3 |
| 9 | 1 | F | 3.8 × 1.1 | ATRT | Carboplatin | C | Fr+P, CS/CR, Th | 2 | 3 | 0.57 | 4 |
| 10 | 15 | F | 2.4 × 1.4 | PTLD | Methotrexate | C | Fr+P, CS/CR, BS, CC | 3 | 3 | 0.29 | 4 |
| 11 | 10 | M | D | AML | Fludarabine | C | D, CS/CR, Th, BS | 4 | 4 | 0.62 | 4 |
| 12 | 17 | F | 5.4 × 2.0 | AML | Fludarabine | C | Fr+P, CS/CR | 2 | 2 | 0.48 | 4 |
| 13 | 13 | F | 1.5 × 0.7 | JMML | BMT | I | Fr, CS/CR | 1 | 1 | 0.17 | 0 |
| 14 | 16 | F | 2.8 × 0.8 | AA | BMT | I | Fr, CS/CR | 1 | 1 | 0.42 | 0 |
| 15 | 17 | M | 1.3 × 1.1 | AML | Cyclosporine | I | P, CS/CR | 1 | 1 | 0.06 | 1 |
| 16 | 17 | F | 0 | AML | BMT | I | NA | 1 | 0 | 0.02 | 0 |
| 17 | 1 | M | 2.8 × 0.5 | RMS | BMT | I | Fr, CS/CR | 1 | 1 | 0.15 | 2 |
| 18 | 7 | M | 3.9 × 1.9 | ATRT | Bevacizumab | O | Fr, CS/CR | 1 | 1 | 0.51 | 2 |
| 19 | 16 | M | 7.9 × 2.4 | ESRD | Uremia | O | Fr+P, CS/CR | 2 | 2 | 0.57 | 3 |
Note:—AA indicates aplastic anemia; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ATRT, atypical teratoid/rhabdoid tumor; %ADC red., percentage ADC reduction; BS, brain stem; CC, corpus callosum; CR, corona radiata; CS, centrum semiovale; D, diffuse; Dx, diagnosis; ESRD, end-stage renal disease; Fr, frontal; JMML, juvenile myelomonocytic leukemia; NA, not applicable; P, parietal; PTLD, post-transplant lymphoproliferative disorder; RMS, rhabdomyosarcoma; Th, thalami.